88 results match your criteria: "Guizhou University School of Medicine[Affiliation]"
Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno-Therapy.
J Labelled Comp Radiopharm
November 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Peking University Cancer Hospital & Institute, Beijing, China.
Immune checkpoint therapy has emerged as an effective treatment option for various types of cancers. Key immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte activation gene 3 (LAG-3), have become pivotal targets in cancer immunotherapy. Antibodies designed to inhibit these molecules have demonstrated significant clinical efficacy.
View Article and Find Full Text PDFCelastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer.
Cancer Cell Int
October 2024
College of Biology and Environmental Engineering, Guiyang University, Guiyang, Guizhou, China, 550005.
Article Synopsis
- - Prostate cancer is a major health issue for men, highlighting the need for improved detection and treatment options, with HSP90AB1 and PARP1 identified as potential targets.
- - The study showed that reducing HSP90AB1 levels made prostate cancer cells more sensitive to the PARP inhibitor olaparib, and combining olaparib with celastrol (an HSP90 inhibitor) led to significantly decreased cell survival and enhanced DNA damage.
- - Findings suggest that the concurrent targeting of HSP90AB1 and PARP1, particularly through the combination of celastrol and olaparib, could be an effective new strategy for treating prostate cancer.
Construction and preclinical evaluation of a I-labelled bispecific antibody targeting PD-L1 and PD-L2.
Eur J Nucl Med Mol Imaging
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Peking University, No. 52 Fu-Cheng Rd, Beijing, 100142, People's Republic of China.
Article Synopsis
- The study focused on developing a bispecific antibody, NB12, that targets PD-L1 and PD-L2, aimed at monitoring cancer patient responses to immune checkpoint inhibitors (ICI) through a radiotracer called [I]I-NB12.
- In vitro testing showed that [I]I-NB12 had a high affinity for its targets, was effectively taken up by certain cancer cells, and demonstrated favorable pharmacokinetics.
- Micro-PET/CT imaging indicated that [I]I-NB12 successfully accumulated in tumor regions, confirming its potential for dynamic imaging in cancer diagnostics.
Preclinical Evaluation and Pilot Clinical Study of F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2.
ACS Pharmacol Transl Sci
June 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Beijing 100142, China.
Article Synopsis
- ACE2 is the primary receptor that SARS-CoV-2 uses to enter cells, making it a key target for studying COVID-19.
- A new PET imaging probe called [F]AlF-DX600-BCH was created to visualize ACE2 expression in living organisms and track how therapies affect it.
- Initial studies showed that the probe effectively targets ACE2 in tissues like the kidneys and reproductive system, suggesting it could help noninvasively map ACE2 distribution.
PGE2 binding to EP2 promotes ureteral stone expulsion by relaxing ureter via the cAMP-PKA pathway.
BMC Urol
June 2024
Department of Urology, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, China.
Background: This study investigated the relaxation effect of PGE2 on the ureter and its role in promoting calculi expulsion following calculi development.
Methods: By using immunofluorescence and Western blot, we were able to locate EP receptors in the ureter. In vitro experiments assessed the impact of PGE2, receptor antagonists, and agonists on ureteral relaxation rate.
Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.
Biomed Pharmacother
June 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China; Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, Guangdong 518055, China. Electronic address:
Article Synopsis
- The study addresses the challenge of efficiently screening patients for responsiveness to immunotherapy in cancer treatment, specifically targeting PD1/CTLA4.
- The research involved developing a bispecific antibody (AK104) labeled with radionuclide isotopes and employing immuno-PET imaging to visualize and evaluate the therapeutic impact on PD1/CTLA4-positive T cells in humanized mouse models.
- Findings indicate that the I-AK104 antibody demonstrated high specificity and efficacy in targeting tumor-infiltrating T cells, suggesting it could be a valuable tool for identifying patients who would benefit from immunotherapy.
Correlation between metabolic syndrome and periurethral prostatic fibrosis: results of a prospective study.
BMC Urol
February 2024
Department of Urology, Guizhou Provincial People's Hospital, Guiyang, China.
Article Synopsis
- Prostatic fibrosis, linked to lower urinary tract symptoms (LUTS), often results from excessive myofibroblasts and collagen buildup, and is associated with metabolic syndrome (MetS), a proinflammatory condition that can exacerbate prostate inflammation.
- Clinical data from 108 patients undergoing prostate surgery indicated that those with MetS exhibited significantly more prostatic fibrosis than those without, highlighting a correlation between the number of MetS risk factors and the severity of fibrosis.
- Specific components of MetS, such as central obesity, high fasting glucose, low HDL cholesterol, and high triglycerides, were found to be positively associated with prostatic fibrosis, while elevated blood pressure had no significant impact.
Ontology-based taxonomical analysis of experimentally verified natural and laboratory human coronavirus hosts and its implication for COVID-19 virus origination and transmission.
PLoS One
January 2024
Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America.
Article Synopsis
- To understand COVID-19, it's essential to study all hosts of SARS-CoV-2, leading to the identification of 37 natural and 19 laboratory hosts classified as therian mammals.
- The analysis revealed that specific mouse models with genetically modified human proteins are particularly susceptible to coronaviruses, highlighting the importance of these proteins in viral severity.
- The study proposes a MOVIE model to explain the virus's variations and immune evasion in animal hosts, which might have influenced the COVID-19 pandemic's progression.
An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
Int J Pharm
February 2024
Guizhou University School of Medicine, Guiyang 550025, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China. Electronic address:
Background And Purpose: Some kinds of antibody-drug conjugate (ADC) with high affinity to Nectin-4 have demonstrated breakthrough progress in the third-line setting for bladder cancer. However, many patients are still difficult to benefit from treatment based on the heterogeneity of tumour. As the most advanced auxiliary treatment technology, treatment visualization can most intuitively predict the effectiveness of drug treatment, and timely detect the occurrence of drug resistance.
View Article and Find Full Text PDFConstruction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer.
Biomed Pharmacother
December 2023
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Peking University, No. 52 Fu-Cheng Rd., 100142 Beijing, People's Republic of China. Electronic address:
Article Synopsis
- The study aimed to create a new tracer that targets PD-L2 to monitor its expression and help identify patients who could benefit from immune checkpoint inhibitor therapy.
- Methodologies included radiolabeling the PD-L2 antibody, evaluating its stability and affinity, and using Micro-PET/CT imaging to assess tumor uptake in mice.
- Results showed high radiochemical yield and purity of the tracer, with significant tumor uptake, suggesting its potential for clinical application in screening patients for ICI therapy.
The Increased TIGIT-Expressing CD3CD56 Cells Are Associated with Coronary Artery Disease and Its Inflammatory Environment.
Inflammation
October 2023
Department of Cardiology, The Affiliated Hospital of Guizhou Medical University, Guiyang City, People's Republic of China.
Article Synopsis
- The study explored the relationship between TIGIT-expressing TNKS cells and coronary artery disease (CAD), finding significant increases in these cells among patients with acute and chronic coronary syndromes compared to controls.
- The presence of TIGIT-expressing TNKS was identified as an independent predictor for CAD, and these cells showed a positive correlation with the severity of atherosclerotic lesions measured by the Gensini score.
- The research indicated that the inflammatory environment, influenced by interleukin signals, enhances TIGIT expression in TNKS, and that specific inhibitors can suppress this upregulation linked to CAD progression.
PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer.
J Transl Med
July 2023
Laboratory of Animal Genetics, Breeding and Reproduction in the Plateau Mountainous Region (Ministry of Education), College of Life Sciences, Guizhou University, Guiyang, 550025, Guizhou, China.
Article Synopsis
- Prostate cancer (PCa) is a common type of cancer in men, and the Bloom's syndrome protein (BLM) is being studied as a potential biomarker linked to its development and progression, though the mechanisms of BLM regulation in PCa are not well understood.
- Research methods included analyzing human tissue samples for BLM expression and conducting various laboratory assays to assess its role in PCa cell behavior, focusing on how BLM interacts with other proteins like PARP1.
- Findings showed that higher levels of BLM correlated with worse outcomes in PCa patients and that reducing BLM expression hindered cancer cell growth and spread; importantly, PARP1 was found to modulate BLM expression through regulatory interactions
Comparison of renal clearance of [F]AlF-RESCA-HER2-BCH and [F]AlF-NOTA-HER2-BCH in mice and breast cancer patients.
Eur J Nucl Med Mol Imaging
July 2023
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Purpose: A novel HER2 affibody-based molecular probe, [F]AlF-RESCA-HER2-BCH, was developed for reducing renal uptake, evaluated, and compared with [F]AlF-NOTA-HER2-BCH.
Methods: In preclinical studies, micro-PET/CT was performed using HER2-positive gastric cancer patient-derived xenografts (PDX) model at 0.5-1 (dynamic), 2, 4, and 6 h post-injection.
Correlation of apolipoprotein A-I with T cell subsets and interferon-ү in coronary artery disease.
Immun Inflamm Dis
March 2023
Department of cardiology, The Affiliated Hospital of Guizhou Medical University, Guiyang city, Guizhou Province, People's Republic of China.
Background: The association of Apolipoprotein A-I (APOAI) with T cell subsets and interferon-ү (IFN-γ) in patients with coronary artery disease (CAD) has been not reported. Thus, this study aimed to investigate the association of APOAI with T cell subsets and IFN-γ in CAD.
Methods: This study included a total of 107 patients with CAD including acute coronary syndrome and chronic coronary syndrome.
Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging.
Mol Pharm
February 2023
Guizhou University School of Medicine, Guiyang, Guizhou550025, China.
Prostate-specific membrane antigen (PSMA) is a prostate cancer target that plays a crucial role in prostate cancer diagnosis and therapy. Herein, a novel dual-targeted imaging probe, [Ga]Ga-FAPI-PSMA, was prepared by radiolabeling conjugated DOTA-FAPI-PSMA with the short half-life radionuclide gallium-68 (Ga), which is dedicated to prostate cancer diagnostic imaging. In vitro, [Ga]Ga-FAPI-PSMA had higher affinity for the PSMA and FAP high-expressing cell lines 22Rv1 and U87 MG with IC values of 4.
View Article and Find Full Text PDFConstruction and Preclinical Evaluation of a I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer.
Mol Pharm
February 2023
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Peking University, No. 52 Fu-Cheng Rd., 100142 Beijing, People's Republic of China.
Programmed cell death-ligand 2 (PD-L2) is an important emerging molecule of the immune checkpoint, which is closely related to the prognosis of patients with immune checkpoint inhibitor (ICI) therapy. The quantification of PD-L2 can provide a potential reference for patients who benefit from ICI treatment. In this study, we used iodine isotope (I)-labeled PD-L2 antibody (ATL2) to noninvasively detect PD-L2 expression in mice with human lung adenocarcinoma A549 cell lines.
View Article and Find Full Text PDFHyperhomocysteinemia exacerbates acute kidney injury increased mitochondrial damage.
Front Physiol
October 2022
Department of Nephrology, Guizhou Provincial Institute of Nephritic & Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
Article Synopsis
- Acute kidney injury (AKI) is a serious and complicated condition linked to higher rates of in-hospital death, and hyperhomocysteinemia (HHcy) is increasingly associated with various kidney diseases, including AKI.
- Researchers studied how HHcy impacts AKI caused by cisplatin in mice and in cultured kidney cells, finding that HHcy worsens kidney damage, mitochondrial dysfunction, and triggers more cell death.
- The study suggests that targeting HHcy levels or protecting against mitochondrial damage could offer new ways to prevent or slow down the progression of AKI.
Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
Mol Pharm
November 2022
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Article Synopsis
- The PD-1/PD-L1 pathway is crucial for tumor immunotherapy, with research focusing on inhibitors like the anti-PD-L1 monoclonal antibody CS1001.
- I-labeled CS1001, a radioactive molecular probe, demonstrates high binding specificity to PD-L1 in tumor cells and offers insights from various clinical trials.
- The study utilized micro-PET imaging to show that I-CS1001 has significantly higher uptake in tumor models expressing human PD-L1 compared to other PD-L1 targeting peptides, suggesting a promising method for monitoring PD-L1 expression in tumors.
The relationship between soluble lymphocyte activation gene-3 and coronary artery disease.
Front Cardiovasc Med
September 2022
Department of Cardiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Article Synopsis
- The study examined the levels of soluble lymphocyte activation gene 3 (sLAG3) in 49 coronary artery disease (CAD) patients and 17 controls, finding that sLAG3 levels were significantly lower in CAD patients.
- The research utilized ELISA to measure sLAG3 levels and analyzed other clinical variables, revealing a negative association between sLAG3 levels and CAD, body mass index (BMI), and diabetes mellitus.
- The findings suggest that reduced sLAG3 might be a potential risk factor for developing CAD, though it did not correlate with the severity of the disease as measured by Gensini scores or ejection fraction.
High in-vivo stability in preclinical and first-in-human experiments with [F]AlF-RESCA-MIRC213: a F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers.
Eur J Nucl Med Mol Imaging
January 2023
Guizhou University School of Medicine, Guizhou University, Guiyang, 550025, China.
Article Synopsis
- The study evaluated the first use of an F-labeled anti-HER2 nanobody, MIRC213, as a PET radiotracer for imaging HER2-positive cancers in humans.
- MIRC213 was produced from E. coli and modified to enhance stability, achieving high radiochemical purity and yield, suitable for clinical applications.
- PET/CT imaging trials in breast cancer patients demonstrated effective cellular uptake and binding affinity, promising outcomes for HER2-targeted imaging.
Construction of a I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors.
Mol Pharm
October 2022
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China.
Article Synopsis
- Mesothelin (MSLN) is a significant biomarker for various solid tumors, making it a targeted area for cancer immunotherapy.
- The study utilized iodine-labeled antibodies specific to MSLN to effectively visualize its expression in colon cancer in mice.
- Results showed that the iodine-labeled antibodies had high uptake in tumors with MSLN overexpression while maintaining a low presence in normal tissues, indicating their potential as a noninvasive diagnostic tool.
Construction of a novel rabbit model of ureteral calculi implanted with flowable resin.
BMC Urol
July 2022
Department of Urology, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, China.
Article Synopsis
- The study aimed to explore the changes in the body caused by hydronephrosis due to ureteral obstruction from calculi, using a new rabbit model with injected flowable resin to simulate stone formation.
- Forty rabbits were split into two groups; one had resin injected to create stones, while the other received saline as a control. Tests, including X-rays and blood tests, tracked the effects of the obstruction over a week.
- The results showed successful model creation in 17 rabbits, with noticeable obstruction and kidney damage present, but most physiological indicators returned to normal by the third day post-surgery, suggesting a reliable method for future studies.
TRIM72-mediated degradation of the short form of p62/SQSTM1 rheostatically controls selective autophagy in human cells.
Mil Med Res
June 2022
Department of Anesthesiology, Wenzhou Key Laboratory of Perioperative Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
The P.R.OS.T.A.T.E Nomogram for the Preoperative Prediction of Clinical Efficacy of Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients.
Clin Interv Aging
June 2022
Department of Urology, Guizhou Provincial People's Hospital, Guiyang, People's Republic of China.
Purpose: Transurethral resection of the prostate (TURP) is often indicated for benign prostatic hyperplasia (BPH). Some patients, however, fail to adequately respond to these interventions. Accordingly, a powerful prediction model for TURP efficacy is warranted.
View Article and Find Full Text PDFMuscle strength performed better than muscle mass in identifying cognitive impairment risk in maintenance hemodialysis patients.
Eat Weight Disord
October 2022
Renal Division, Department of Medicine, Guizhou Provincial People's Hospital, Guizhou Provincial Institute of Nephritic and Urinary Disease, Guiyang, China.
Objectives: The association between muscle mass and cognitive impairment (CI) is conflicting. We aimed to evaluate and compare the associations of muscle strength, muscle mass and CI risk in maintenance hemodialysis (MHD) patients.
Methods: We conducted a multicenter, cross-sectional study.